세계의 mRNA 합성 및 제조 시장 : 서비스별, 서비스 유형별, 제조 공정별, 제조 규모별, 기술별, 응용 분야별, 용도별, 최종 사용자별, 예측(2025-2030년)

The mRNA Synthesis & Manufacturing Market was valued at USD 2.48 billion in 2023 and is projected to grow to USD 2.71 billion in 2024, with a CAGR of 9.35%, reaching USD 4.65 billion by 2030.

mRNA synthesis and manufacturing have emerged as transformative technologies in the biotechnology sector, driving innovation and redefining therapeutic and vaccine development. In the wake of recent global health challenges, the demand for efficient, scalable, and high-quality mRNA production has accelerated. This dynamic environment calls for a nuanced understanding of the core processes, market drivers, and strategic initiatives that are shaping the future.

The landscape of mRNA production is marked by rapid technological advancements and evolving regulatory frameworks. Novel techniques in mRNA capping, formulation, in vitro transcription, and purification are not only enhancing the speed and quality of production but are also setting new industry standards. As the market expands, stakeholders are increasingly confronted with complex decisions regarding process selection, technology adaptation, and resource allocation.

Industry participants-from research institutes to major pharmaceutical corporations-are investing in next-generation manufacturing capabilities to maintain competitive advantage. The integration of advanced enzymatic capping and cap analogue methodologies, combined with the evolution of storage and distribution logistics, is streamlining the delivery of both client-specific and standardized mRNA products. This introductory section sets the stage for an in-depth exploration of the various elements that influence the mRNA synthesis and manufacturing market, providing a framework for further analysis and strategic planning.

Transformative Shifts in the mRNA Synthesis & Manufacturing Landscape

The mRNA synthesis and manufacturing industry is witnessing transformative shifts that are redefining traditional paradigms and paving the way for innovative growth. Established companies and emerging players alike are embracing technological enhancements and novel approaches to seize new opportunities, driven by unprecedented global demand.

Rapid advancements in genetic engineering and codon optimization have led to significant improvements in in vitro transcription processes. The integration of automated workflows has not only reduced production timelines but has also increased scalability and reproducibility-critical factors in responding to urgent healthcare needs. Moreover, regulatory evolutions, driven by the urgency of public health crises, have accelerated the adoption of new manufacturing technologies, enabling faster approval cycles and enhanced transparency in quality control.

These transformative shifts are amplified by rigorous investments in advanced lipid nanoparticle (LNP) formulation and enzymatic capping technologies. The combined evolution of these methodologies offers a robust framework for addressing both therapeutic and vaccine applications. Additionally, enhancements in storage and distribution logistics have been pivotal in ensuring that high-quality mRNA products reach their intended markets efficiently, even in the face of complex global supply chain challenges.

The market today is defined by a shift towards customization and specific client requirements. Custom mRNA synthesis, driven by client-specific orders and tailored research specifications, now stands shoulder-to-shoulder with conventional approaches that focus on cataloged or off-the-shelf mRNA selections. This evolution reflects the industry's commitment to meeting diverse demands, ranging from experimental research to large-scale clinical applications. In essence, these market shifts underscore a transition from conventional mass production to a more agile, adaptable, and precision-focused manufacturing ecosystem.

Key Segmentation Insights in mRNA Manufacture

A detailed examination of market segmentation in mRNA synthesis and manufacturing reveals multiple dimensions that cater to specific requirements and application domains. Analyzing the market from the perspective of services, the study of capping and tailing, formulation, in silico design, modification and optimization, purification and quality control, storage and distribution, and template DNA preparation provide a foundational framework for understanding technological intricacies. Moreover, when considering service type distinctions, the market is evaluative of both custom mRNA synthesis and standard mRNA production. The former is intricately linked to client-specific mRNA orders and tailored research specifications, while the latter encompasses cataloged mRNA variants and off-the-shelf mRNA selections, reflecting diverse operational models.

The segmentation analysis based on the manufacturing process highlights innovations such as advanced LNP formulation technology, enzymatic capping combined with cap analogues, genetic engineering with codon optimization, as well as in vitro transcription techniques, plasmid DNA template use, polyadenylation, and RNA purification. This perspective captures the critical technological and process-driven factors that differentiate products and influence market positioning. Equally important is the segmentation based on manufacturing scale, which concentrates on the practicalities and challenges of commercial scale, lab scale, and pilot scale operations, each presenting unique operational frameworks and economic implications.

Further segmentation based on technology introduces the dichotomy between in vitro synthesis and in vivo synthesis, each representing specialized technological approaches with their own advantages and limitations. Application-based segmentation further dissects the market into therapeutics and vaccines. Here, the therapeutic segment, with its focus on cancer, infectious diseases, and rare diseases, demonstrates a complex interplay of clinical requirements and innovative solutions. Meanwhile, the vaccine segment diversifies into prophylactic vaccines and therapeutic vaccines, highlighting a strategic balance between prevention and treatment.

Additional dimensions such as usage and end-user segmentation offer nuanced insights into market dynamics. The usage perspective distinguishes between human and veterinary use, reflecting targeted product design and performance criteria. Meanwhile, end-user segmentation provides clarity by mapping the interrelationships between academic and research institutes, contract manufacturing organizations, and pharmaceutical and biotechnology companies, with further differentiation within academic and research institutes based on government research bodies and university laboratories. This layered segmentation highlights the multifaceted nature of the market, offering a roadmap for tailored strategies and targeted product innovations that meet the precise needs of different customer segments.

Based on Services, market is studied across Capping & Tailing, Formulation, In Silico Design, Modification & Optimization, Purification & Quality Control, Storage & Distribution, and Template DNA Preparation.

Based on Service Type, market is studied across Custom mRNA Synthesis and Standard mRNA Production. The Custom mRNA Synthesis is further studied across Client-Specific mRNA Orders and Tailored Research Specifications. The Standard mRNA Production is further studied across Cataloged mRNA Variants and Off-the-Shelf mRNA Selections.

Based on Manufacturing Process, market is studied across Advanced LNP Formulation Technology, Enzymatic Capping & Cap Analogues, Genetic Engineering & Codon Optimization, In Vitro Transcription, Plasmid DNA Template, Polyadenylation, and RNA Purification Techniques.

Based on Manufacturing Scale, market is studied across Commercial Scale, Lab Scale, and Pilot Scale.

Based on Technology, market is studied across In Vitro Synthesis and In Vivo Synthesis.

Based on Application, market is studied across Therapeutics and Vaccines. The Therapeutics is further studied across Cancer, Infectious Diseases, and Rare Diseases. The Vaccines is further studied across Prophylactic Vaccines and Therapeutic Vaccines.

Based on Usage, market is studied across Human Use and Veterinary Use.

Based on End-User, market is studied across Academic & Research Institutes, Contract Manufacturing Organizations, and Pharmaceutical & Biotechnology Companies. The Academic & Research Institutes is further studied across Government Research Bodies and University Laboratories.

Key Regional Insights Influencing Market Dynamics

The geographic dimension of mRNA synthesis and manufacturing is characterized by varied regional trends and strategic imperatives. Analysis across the Americas has revealed robust investment in state-of-the-art research and development facilities, driven by both private and public funding that positions the region at the forefront of technological innovation. This dynamic is propelled by strong collaborations between academic institutions and the pharmaceutical industry, fostering an ecosystem conducive to rapid product iteration and market responsiveness.

Turning to the Europe, Middle East & Africa region, the focus is on regulatory harmonization and quality control standards that are essential for both local markets and broader international trade. Increased governmental support paired with strategic partnerships in biotech research has enabled significant inroads in mRNA technology. This region's evolved regulatory framework not only supports innovative research but also accelerates the path from laboratory discovery to clinical application, thereby enhancing overall market competitiveness.

In the Asia-Pacific region, the market is buoyed by rapid industrial growth, extensive investments in manufacturing infrastructure, and a burgeoning talent pool of scientific professionals. Innovations here are underscored by a commitment to scale commercial production while maintaining rigorous standards in laboratory research. The integration of advanced manufacturing processes with local expertise supports both customized and standardized production models, driving efficiency and ensuring that emerging products meet global quality benchmarks. Together, these regional insights play a pivotal role in shaping market strategies and investment decisions for companies operating across diverse geographies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Shaping Industry Innovation

The competitive landscape is defined by the presence of several key companies that continuously drive innovation and market growth in mRNA synthesis and manufacturing. Leading firms such as Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited and Bio-Synthesis Inc. have been instrumental in advancing client-specific service offerings, leveraging their robust research capabilities to meet specialized demands. Creative Biogene and Creative Biolabs contribute significantly by combining tailored research with comprehensive standard production platforms, thereby bridging the gap between novelty and consistency.

Another critical group includes Croyez Bioscience Co., Ltd. and Danaher Corporation, both of which invest heavily in state-of-the-art production technologies that improve process automation and yield. FUJIFILM Wako Pure Chemical Corporation and Genewiz by Azenta Life Sciences focus on providing high-quality enzymes and reagents that are essential to enhancing the precision and robustness of mRNA manufacturing. GenScript Biotech Corporation and Jena Bioscience GmbH by Enzo Biochem Inc. continue to influence the market through their dedicated advancements in process optimization and genetic engineering techniques.

The manufacturing scale is further impacted by major industry leaders such as Lonza Group Ltd. and Merck KGaA, which have set benchmarks in large-scale production workflows as well as quality control mechanisms. New England Biolabs, Inc., alongside PackGene Biotech, Inc. and Promega Corporation, are well-regarded for their contributions to developing efficient pilot and lab scale production systems while maintaining consistency across commercial scale outputs. Companies like Samsung Biologics Co., Ltd. and Sartorius AG have also brought precision and operational excellence to the forefront, expanding production capacities and streamlining logistics.

Additional market influencers include ST Pharm and System Biosciences, LLC, who invest in cutting-edge research and process innovation. Takara Bio Inc. and Telesis Bio Inc. further add to the competitive momentum by focusing on integrated manufacturing solutions that blend in vitro synthesis with advanced analytic capabilities. Thermo Fisher Scientific Inc. and TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, with their diverse service portfolios, have also positioned themselves as leaders in both custom and standard mRNA production methodologies. Finally, WuXi Biologics (Cayman) Inc. rounds out an impressive list of companies dedicated to advancing production capabilities, reinforcing the industry's commitment to quality and innovation at every stage of mRNA synthesis and manufacturing.

The report delves into recent significant developments in the mRNA Synthesis & Manufacturing Market, highlighting leading vendors and their innovative profiles. These include Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited, Bio-Synthesis Inc., Creative Biogene, Creative Biolabs, Croyez Bioscience Co., Ltd., Danaher Corporation, FUJIFILM Wako Pure Chemical Corporation, Genewiz by Azenta Life Sciences, GenScript Biotech Corporation, Jena Bioscience GmbH by Enzo Biochem Inc., Lonza Group Ltd., Merck KGaA, New England Biolabs, Inc., PackGene Biotech, Inc., Promega Corporation, Samsung Biologics Co., Ltd., Sartorius AG, ST Pharm, System Biosciences, LLC, Takara Bio Inc., Telesis Bio Inc., Thermo Fisher Scientific Inc., TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC, and WuXi Biologics (Cayman) Inc. Actionable Recommendations for Industry Leaders in mRNA Manufacturing

In the face of rapid technological evolution and competitive market forces, industry leaders must adopt proactive strategies to maintain and enhance their market positioning. To thrive in this environment, companies should consider the following actionable recommendations:

Invest in Continuous Process Optimization: The rapid pace of technological advancements demands ongoing investments in process innovation. Establish dedicated research and development units to continuously refine production techniques, focusing on areas such as advanced LNP formulation technology, enzymatic capping innovations, and state-of-the-art genetic engineering practices. Regular audits of in vitro transcription, plasmid template preparation, and RNA purification technologies will not only drive operational efficiencies but also ensure compliance with emerging regulatory standards.

Embrace Flexible Production Models: With the market segmented by manufacturing scale-from lab and pilot scale to full commercial production-it is crucial to build adaptive production units that can scale based on demand fluctuations. Flexible manufacturing setups allow firms to optimize resource allocation and manage risks associated with overproduction or underutilization of facilities. Adopting modular manufacturing strategies can help streamline transitions between different production scales, ensuring a seamless response to shifting market dynamics.

Strengthen Collaborative Networks: In today's competitive landscape, forging strategic partnerships is key to unlocking synergies and driving innovation. Collaborations with academic research institutions, government research bodies, and private sector leaders can facilitate the exchange of expertise and best practices. Such networks not only enhance technological capabilities but also provide opportunities for joint research initiatives, faster adoption of breakthrough technologies, and improved market outreach.

Prioritize Technology Integration: With segmentation based on service type and technological approaches-whether in vitro or in vivo synthesis-integrating advanced analytics and process automation is critical. Utilize digital twin technology and real-time data monitoring systems to optimize manufacturing workflows, improve quality control, and reduce production bottlenecks. Embracing Industry 4.0 principles will enable organizations to unlock efficiencies and make data-driven decisions that enhance overall operational performance.

Diversify Product Portfolios: Expanding product offerings to include both custom mRNA synthesis and standardized production allows companies to serve a broader segment of the market. By tailoring solutions to meet specific client needs-whether for client-specific orders or cataloged mRNA variants-businesses can capture a wider audience while mitigating risks associated with relying on a single product line. Diversification also opens up new revenue streams, enhances market resilience, and fosters a customer-centric approach to product development.

Focus on Regulatory Compliance and Quality Assurance: Given the critical impact of quality control in mRNA manufacturing, robust systems to ensure regulatory compliance are indispensable. Regular training, process audits, and investments in advanced quality control technologies will minimize risks and build consumer trust. Establishing transparent and rigorous documentation practices is essential for navigating regulatory landscapes and sustaining long-term market viability.

Invest in Workforce Development: As technological complexity increases, so does the need for skilled personnel. Industry leaders should prioritize training and development programs to equip their workforce with the latest techniques in mRNA synthesis and manufacturing. Enhancing technical expertise not only improves operational efficiency but also drives innovation, ensuring that companies remain agile in the face of emerging industry trends.

Pursue Market Expansion Strategically: Finally, a thorough understanding of regional market dynamics-across the Americas, Europe, Middle East & Africa, and Asia-Pacific-should inform expansion strategies. Tailoring market entry plans and product offerings to the unique demands and regulatory environments of each region can unlock new opportunities and bolster international growth. Overall, strategic investments in process innovation, talent development, and robust quality assurance practices will position industry leaders for sustainable success in a competitive and rapidly evolving market.

Conclusion: Embracing Innovation for Future Growth

The mRNA synthesis and manufacturing landscape is characterized by rapid innovation, complex segmentation, and expansive market opportunities. As industry leaders continue to leverage advanced manufacturing processes, integrate cutting-edge technology solutions, and foster strategic collaborations, the stage is set for a new era of precision medicine and breakthrough therapeutic solutions.

This comprehensive analysis underscores the importance of continuous process optimization, flexible production models, and the integration of state-of-the-art technologies. The segmentation insights reveal a market that is as diverse in its applications as it is in its methodologies. Whether it is the intricate processes involved in enzymatic capping, the precision of genetic engineering, or the adaptability required for various manufacturing scales, each facet contributes to a vibrant and competitive ecosystem.

Moreover, regional insights highlight that global collaboration and tailored strategies are pivotal to navigating the unique challenges and opportunities present in different geographies. With major players driving innovation and setting high benchmarks for quality and efficiency, the future of mRNA synthesis and manufacturing looks not only promising but fundamentally transformative.

In conclusion, by embracing a culture of innovation, proactive market expansion, and continuous improvement, stakeholders can unlock unprecedented growth and revolutionize the manner in which life-saving therapies and vaccines are developed. The journey ahead calls for a steadfast commitment to quality, agility, and visionary leadership, ensuring that the full potential of mRNA technology is realized in both current and future applications.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increasing incidence of infectious diseases across the globe
    • 5.1.1.2. Partnerships between biotech firms and educational institutions
  • 5.1.2. Restraints
    • 5.1.2.1. Complex and costly manufacturing processes associated with mRNA
  • 5.1.3. Opportunities
    • 5.1.3.1. Emerging mRNA applications in cancer therapeutics

• 5.1.3.2. Integrating data analytics and AI to enhance mRNA sequence design and optimization
• 5.1.3.3. Significant funding and investment from governments and private entities
• 5.1.4. Challenges
  • 5.1.4.1. Ethical concerns associated with mRNA synthesis & manufacturing

• 5.1.4.2. Diificulties in navigating the complex regulatory landscape for mRNA
• 5.2. Market Segmentation Analysis
  • 5.2.1. Services: Increasing usage of the modification & optimization services focuses on enhancing stability and translational efficiency
  • 5.2.2. Service Type: Significant custom mRNA synthesis utilization in delivering personalized solutions, attracting biotech startups and research institutions
  • 5.2.3. Manufacturing Process: Substantial adoption of genetic engineering & codon optimization process for maximizing protein yield and ensuring optimal gene expression
  • 5.2.4. Manufacturing Scale: Increased commercial scale production driven by growing pharmaceutical companies and established biotech firms
  • 5.2.5. Technology: Rising adoption of in vitro synthesis due to its rapid production cycle and the control level offered over the synthesis process
  • 5.2.6. Application: Expanding role of mRNA synthesis & manufacturing for the vaccines
  • 5.2.7. Usage: Evolving need for mRNA-based therapeutics and vaccines for humans usage
  • 5.2.8. End-User: Pharmaceutical & biotechnology companies are heavily invested in mRNA technology for its potential in vaccine and therapeutic development
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. mRNA Synthesis & Manufacturing Market, by Services

• 6.1. Introduction
• 6.2. Capping & Tailing
• 6.3. Formulation
• 6.4. In Silico Design
• 6.5. Modification & Optimization
• 6.6. Purification & Quality Control
• 6.7. Storage & Distribution
• 6.8. Template DNA Preparation

7. mRNA Synthesis & Manufacturing Market, by Service Type

• 7.1. Introduction
• 7.2. Custom mRNA Synthesis
  • 7.2.1. Client-Specific mRNA Orders
  • 7.2.2. Tailored Research Specifications
• 7.3. Standard mRNA Production
  • 7.3.1. Cataloged mRNA Variants
  • 7.3.2. Off-the-Shelf mRNA Selections

8. mRNA Synthesis & Manufacturing Market, by Manufacturing Process

• 8.1. Introduction
• 8.2. Advanced LNP Formulation Technology
• 8.3. Enzymatic Capping & Cap Analogues
• 8.4. Genetic Engineering & Codon Optimization
• 8.5. In Vitro Transcription
• 8.6. Plasmid DNA Template
• 8.7. Polyadenylation
• 8.8. RNA Purification Techniques

9. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale

• 9.1. Introduction
• 9.2. Commercial Scale
• 9.3. Lab Scale
• 9.4. Pilot Scale

10. mRNA Synthesis & Manufacturing Market, by Technology

• 10.1. Introduction
• 10.2. In Vitro Synthesis
• 10.3. In Vivo Synthesis

11. mRNA Synthesis & Manufacturing Market, by Application

• 11.1. Introduction
• 11.2. Therapeutics
  • 11.2.1. Cancer
  • 11.2.2. Infectious Diseases
  • 11.2.3. Rare Diseases
• 11.3. Vaccines
  • 11.3.1. Prophylactic Vaccines
  • 11.3.2. Therapeutic Vaccines

12. mRNA Synthesis & Manufacturing Market, by Usage

• 12.1. Introduction
• 12.2. Human Use
• 12.3. Veterinary Use

13. mRNA Synthesis & Manufacturing Market, by End-User

• 13.1. Introduction
• 13.2. Academic & Research Institutes
  • 13.2.1. Government Research Bodies
  • 13.2.2. University Laboratories
• 13.3. Contract Manufacturing Organizations
• 13.4. Pharmaceutical & Biotechnology Companies

14. Americas mRNA Synthesis & Manufacturing Market

• 14.1. Introduction
• 14.2. Argentina
• 14.3. Brazil
• 14.4. Canada
• 14.5. Mexico
• 14.6. United States

15. Asia-Pacific mRNA Synthesis & Manufacturing Market

• 15.1. Introduction
• 15.2. Australia
• 15.3. China
• 15.4. India
• 15.5. Indonesia
• 15.6. Japan
• 15.7. Malaysia
• 15.8. Philippines
• 15.9. Singapore
• 15.10. South Korea
• 15.11. Taiwan
• 15.12. Thailand
• 15.13. Vietnam

16. Europe, Middle East & Africa mRNA Synthesis & Manufacturing Market

• 16.1. Introduction
• 16.2. Denmark
• 16.3. Egypt
• 16.4. Finland
• 16.5. France
• 16.6. Germany
• 16.7. Israel
• 16.8. Italy
• 16.9. Netherlands
• 16.10. Nigeria
• 16.11. Norway
• 16.12. Poland
• 16.13. Qatar
• 16.14. Russia
• 16.15. Saudi Arabia
• 16.16. South Africa
• 16.17. Spain
• 16.18. Sweden
• 16.19. Switzerland
• 16.20. Turkey
• 16.21. United Arab Emirates
• 16.22. United Kingdom

17. Competitive Landscape

• 17.1. Market Share Analysis, 2023
• 17.2. FPNV Positioning Matrix, 2023
• 17.3. Competitive Scenario Analysis
  • 17.3.1. TriLink and Alphazyme's CleanScribe RNA Polymerase revolutionizes mRNA synthesis with reduced dsRNA formation
  • 17.3.2. Partnership between Telesis Bio and Beckman Coulter Life Sciences transforms DNA and mRNA synthesis through scalable and high-fidelity biofoundries
  • 17.3.3. Strategic partnership in mRNA synthesis, Primrose Bio, and ExPLoRNA transform therapeutic advancements through innovation
  • 17.3.4. Strategic acquisition of echelon biosciences by VION biosciences to increase mRNA therapies and life science offerings
  • 17.3.5. GSK collaborates with Touchlight to revolutionize mRNA vaccine production using advanced dbDNA technology
  • 17.3.6. Applied DNA secures patent for innovative Linea IVT technology advancing mRNA synthesis efficiency
  • 17.3.7. WACKER unveils mRNA competence center in Germany to expand global pandemic preparedness and biotech innovation
  • 17.3.8. Takara Bio launched genetically enhanced PrimeCap T7 RNA polymerase, revolutionizing safe mRNA synthesis for advanced therapeutics
  • 17.3.9. TriLink BioTechnologies Expands Late-Phase mRNA Drug Manufacturing with New San Diego Facility
  • 17.3.10. Strategic alliance between PackGene Biotech and Kudo Biotechnology transforms global mRNA manufacturing landscape with comprehensive end-to-end solutions
• 17.4. Strategy Analysis & Recommendation
  • 17.4.1. GenScript Biotech Corporation
  • 17.4.2. Thermo Fisher Scientific Inc.
  • 17.4.3. Samsung Biologics Co., Ltd.
  • 17.4.4. Danaher Corporation

Companies Mentioned

• 1. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
• 2. Bio-Synthesis Inc.
• 3. Creative Biogene
• 4. Creative Biolabs
• 5. Croyez Bioscience Co., Ltd.
• 6. Danaher Corporation
• 7. FUJIFILM Wako Pure Chemical Corporation
• 8. Genewiz by Azenta Life Sciences
• 9. GenScript Biotech Corporation
• 10. Jena Bioscience GmbH by Enzo Biochem Inc.
• 11. Lonza Group Ltd.
• 12. Merck KGaA
• 13. New England Biolabs, Inc.
• 14. PackGene Biotech, Inc.
• 15. Promega Corporation
• 16. Samsung Biologics Co., Ltd.
• 17. Sartorius AG
• 18. ST Pharm
• 19. System Biosciences, LLC
• 20. Takara Bio Inc.
• 21. Telesis Bio Inc.
• 22. Thermo Fisher Scientific Inc.
• 23. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
• 24. WuXi Biologics (Cayman) Inc